RETAFIT 4

Retatrutide is a novel triple hormone receptor agonist that simultaneously targets GIP, GLP-1, and glucagon receptors, designed for the treatment of obesity and metabolic disorders. This tri-agonist mechanism represents an advanced approach to metabolic regulation by combining the effects of incretin hormones with glucagon receptor activation. Retatrutide enhances glucose-dependent insulin secretion, suppresses glucagon when glucose is elevated, increases energy expenditure, delays gastric emptying, and significantly reduces appetite. Its pharmacokinetics support once-weekly subcutaneous administration. Early-stage clinical trials have demonstrated impressive weight loss effects, with reductions of up to 24% of body weight in some participants, along with improved glycemic parameters. The compound is still under investigation and not yet approved, but its efficacy profile suggests potential advantages over current mono- or dual-agonist therapies. Caution is warranted in individuals with a history of medullary thyroid carcinoma or MEN 2, in line with other incretin-based therapies.